These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29577969)

  • 21. The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole.
    Ferraz ML; Gazzinelli RT; Alves RO; Urbina JA; Romanha AJ
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1359-64. PubMed ID: 17220408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New process for screening of drugs in experimental infection with Trypanosoma cruzi].
    Campos R; Amato Neto V; de Souza HB; Braz LM
    Rev Inst Med Trop Sao Paulo; 1991; 33(4):325-7. PubMed ID: 1844956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection.
    Guedes-da-Silva FH; Batista DG; da Silva CF; Meuser MB; Simões-Silva MR; de Araújo JS; Ferreira CG; Moreira OC; Britto C; Lepesheva GI; Soeiro Mde N
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7564-70. PubMed ID: 26416857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The β-blocker carvedilol and the benznidazole modulate the cardiac immune response in the acute infection induced by Colombian strain of the Trypanosoma cruzi.
    Horta AL; Figueiredo VP; Leite ALJ; Costa GP; Menezes APJ; Ramos CO; Pedrosa TCF; Bezerra FS; Vieira PMA; Talvani A
    Mem Inst Oswaldo Cruz; 2018 Oct; 113(11):e180271. PubMed ID: 30365644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trypanosoma cruzi: Induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection.
    Dos Santos FM; Caldas S; de Assis Cáu SB; Crepalde GP; de Lana M; Machado-Coelho GL; Veloso VM; Bahia MT
    Exp Parasitol; 2008 Dec; 120(4):385-90. PubMed ID: 18823980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
    Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD
    PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
    Melo-Filho CC; Braga RC; Muratov EN; Franco CH; Moraes CB; Freitas-Junior LH; Andrade CH
    Eur J Med Chem; 2019 Feb; 163():649-659. PubMed ID: 30562700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection.
    Fernández MC; González Cappa SM; Solana ME
    Exp Parasitol; 2010 Feb; 124(2):172-80. PubMed ID: 19747482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High throughput screening for anti-Trypanosoma cruzi drug discovery.
    Alonso-Padilla J; Rodríguez A
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3259. PubMed ID: 25474364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
    Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
    Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.
    Wong-Baeza C; Nogueda-Torres B; Serna M; Meza-Toledo S; Baeza I; Wong C
    BMC Pharmacol Toxicol; 2015 Apr; 16():10. PubMed ID: 25896924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trypanosoma cruzi-Specific T-Cell Responses to Monitor Treatment Efficacy in Chronic Chagas Disease.
    Albareda MC; Natale MA; Cesar GL; Castro Eiro MD; Alvarez MG; Laucella SA
    Methods Mol Biol; 2019; 1955():339-348. PubMed ID: 30868539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.
    Novaes RD; Santos EC; Cupertino MC; Bastos DS; Oliveira JM; Carvalho TV; Neves MM; Oliveira LL; Talvani A
    Parasitol Res; 2015 Aug; 114(8):2873-81. PubMed ID: 25912691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of novel arylimidamides against Trypanosoma cruzi in vitro.
    DA Silva CF; Daliry A; DA Silva PB; Akay S; Banerjee M; Farahat AA; Fisher MK; Hu L; Kumar A; Liu Z; Stephens CE; Boykin DW; Correia Soeiro MD
    Parasitology; 2011 Dec; 138(14):1863-9. PubMed ID: 21902869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole.
    Caldas S; Santos FM; de Lana M; Diniz LF; Machado-Coelho GL; Veloso VM; Bahia MT
    Exp Parasitol; 2008 Mar; 118(3):315-23. PubMed ID: 17945216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A flow cytometer-based method to simultaneously assess activity and selectivity of compounds against the intracellular forms of Trypanosoma cruzi.
    Miranda CG; Solana ME; Curto MLA; Lammel EM; Schijman AG; Alba Soto CD
    Acta Trop; 2015 Dec; 152():8-16. PubMed ID: 26272680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic efficacy of several nitroimidazoles for experimental Trypanosoma cruzi infections in mice.
    Malanga CM; Conroy J; Cuckler AC
    J Parasitol; 1981 Feb; 67(1):35-40. PubMed ID: 6785408
    [No Abstract]   [Full Text] [Related]  

  • 40. Lack of correlation between in vitro susceptibility to Benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease.
    Villarreal D; Barnabé C; Sereno D; Tibayrenc M
    Exp Parasitol; 2004; 108(1-2):24-31. PubMed ID: 15491545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.